Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Robin Diepstraten

MD PhD student
The SOUND study: Prevalence and (genetic) determinants of ototoxicity during and after childhood cancer treatment.
Phone 088 97 25 633

Over de past decades childhood cancer survival rates have been increased. Hence, more children suffer from direct and late sequelae of their treatment. Ototoxicity, including hearing loss, tinnitus and vertigo, could be one of the direct sequelae of childhood cancer. Previous studies conclude that treatment with platinum chemotherapeutics, cranial irradiation and ENT surgery may be risk factors for ototoxicity. But, there are also treatment components of which we expect that they contribute to ototoxicity in pediatric patients, like antibiotics and diuretics. In the SOUND study (A prospective Study on prevalence and determinants of Ototoxicity dUring treatmeNt of childhooD cancer) we investigate prevalence and determinants of ototoxicity during treatment of pediatric cancer. 

  • Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

    • dec. 2022
    • Franciscus A., Diepstraten, et al
    • Cancers
  • A Study on Prevalence and Determinants of Ototoxicity During Treatment of Childhood Cancer (SOUND)

    • apr. 2022
    • Franciscus A., Diepstraten, et al
    • JMIR Research Protocols
  • Aminoglycoside- and glycopeptide-induced ototoxicity in children

    • dec. 2021
    • F. A., Diepstraten, et al
    • JAC-Antimicrobial Resistance
View all publications